Conflict of interest statement

We would like to thank all investigators and participants in the AMBITION trial and associated substudies, community members, and the funders of the trial. The AMBITION trial was supported by a grant through the European Developing Countries Clinical Trials Partnership (EDCTP), the Swedish International Development Cooperation Agency (TRIA2015-1092), and the Wellcome Trust/Medical Research Council (MRC) UK/UKAID Joint Global Health Trials (MR/P006922/1). Additional funding was provided by the National Institute for Health Research (NIHR) through a Global Health Research Professorship (RP-2017-08-ST2-012, to JNJ) with aid from the UK Government to support global health research. JNJ is funded by the National Institute for Health and Care Research (NIHR) through a Global Health Research Professorship (RP-2017-08-ST2-012) using UK aid from the UK Government to support global health research and received grant payments from the NIHR and EDCTP to his institution. RC received consulting fees to serve as methodologist for the updated WHO guideline on cryptococcal meningitis. TSH and DSL received support for the underlying AMBITION trial to institution from EDCTP, MRC, and Wellcome Trust, UK aid from the UK Government to support global health research, and provision of drug for the underlying AMBITION trial from Gilead. All other authors declare no competing interests. The views expressed in this publication are those of the authors and not necessarily those of the NIHR or the UK Department of Health and Social Care. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The writing of this Comment was supported by a grant from the Bill & Melinda Gates Foundation. We are grateful to Susan L Norris and Rebekah Thomas for providing comments on an earlier draft.